NCT02756572 - Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 22, 2016

Primary Completion Date

March 1, 2020

Study Completion Date

July 1, 2020

Conditions

Blasts 10 Percent or More of Bone Marrow Nucleated CellsChronic Myelomonocytic Leukemia-2High Grade Malignant NeoplasmMyelodysplastic SyndromeMyelodysplastic Syndrome With Excess Blasts-2Myeloid NeoplasmPreviously Treated Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Interventions

DRUG

Cladribine

Given IV

DRUG

Cyclosporine

Given PO

DRUG

Cytarabine

Given IV

BIOLOGICAL

Filgrastim

Given SC

DRUG

Fludarabine Phosphate

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic hematopoietic stem cell transplantation

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Melphalan

Given IV

DRUG

Mitoxantrone Hydrochloride

Given IV

DRUG

Mycophenolate Mofetil

Given PO

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Sirolimus

Given PO

RADIATION

Total-Body Irradiation

Undergo TBI

DRUG

Melphalan Hydrochloride

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER